Immunomodulation to prevent or treat neonatal sepsis: Past, present, and future

Frontiers in Pediatrics

Volumn 6, Issue , 2018, Pages

  Schüller, Simone S ^a,b,c   Kramer, Boris W ^d,e   Villamor, Eduardo ^d,e   Spittler, Andreas ^f   Berger, Angelika ^a   Levy, Ofer ^b,c,g  

^a UNIV KLIN KINDER JUGENDHEILKUNDE   (Austria)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^e MAASTRICHT UNIVERSITY   (Netherlands)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

^g BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

Adjuvant sepsis therapy; Human milk; Immunomodulation; Lactoferrin; Neonatal sepsis; Pentoxifylline; Preterm infant; Probiotics

Indexed keywords

EID: 85052912034     PISSN: None     EISSN: 22962360     Source Type: Journal    
DOI: 10.3389/fped.2018.00199     Document Type: Review

References (240)

1. Soll RF. Progress in the care of extremely preterm infants. JAMA (2015) 314:1007-8. doi: 10.1001/jama.2015.10911
2. Stoll BJ, Hansen NI, Adams-Chapman I, Fanaroff AA, Hintz SR, Vohr B, Higgins RD. National Institute of child health and human development neonatal research network. neurodevelopmental and growth impairment among extremely low-birth-weight infants with neonatal infection. JAMA (2004) 292:2357. doi: 10.1001/jama.292.19.2357
3. Wynn JL, Wong HR, Shanley TP, BizzarroMJ, Saiman L, Polin RA. Time for a neonatal-specific consensus definition for sepsis. Pediatr Crit Care Med. (2014) 15:523-8. doi: 10.1097/PCC.0000000000000157
4. Camacho-Gonzalez A, Spearman PW, Stoll BJ. Neonatal infectious diseases: evaluation of neonatal sepsis. Pediatr Clin North Am. (2013) 60:367-89. doi: 10.1016/j.pcl.2012.12.003
5. Hornik CP, Fort P, Clark RH, Watt K, Benjamin DK, Smith PB, et al. Early and late onset sepsis in very-low-birth-weight infants from a large group of neonatal intensive care units. Early Hum Dev. (2012) 88 (Suppl. 2):S69-74. doi: 10.1016/S0378-3782(12)70019-1
6. Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics (2002) 110:285-91. doi: 10.1542/peds.110.2.285
7. Stoll BJ, Hansen NI, Higgins RD, Fanaroff AA, Duara S, Goldberg R. Very low birth weight preterm infants with early onset neonatal sepsis: the predominance of gram-negative infections continues in the National Institute of Child Health and Human Development Neonatal Research Network, 2002-2003. Pediatr Infect Dis J. (2005) 24:635-9. doi: 10.1097/01.inf.0000168749.82105.64
8. Stoll BJ, Hansen NI, Bell EF, Shankaran S, Laptook AR, Walsh MC, et al. Neonatal Outcomes of Extremely Preterm Infants From the NICHD Neonatal Research Network. Pediatrics (2010) 126:443-56. doi: 10.1542/peds.2009-2959
9. Adams-Chapman I, Stoll BJ. Neonatal infection and long-term neurodevelopmental outcome in the preterm infant. Curr Opin Infect Dis. (2006) 19:290-7. doi: 10.1097/01.qco.0000224825.57976.87
10. Strunk T, Inder T, Wang X, Burgner D, Mallard C, Levy O. Infection-induced inflammation and cerebral injury in preterm infants. Lancet Infect Dis. (2014) 14:751-62. doi: 10.1016/S1473-3099(14)70710-8
11. Goldstein B, Giroir B, Randolph A, International Consensus Conference on Pediatric Sepsis. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics*. Pediatr Crit Care Med. (2005) 6:2-8. doi: 10.1097/01.PCC.0000149131.72248.E6
12. Wynn JL. Defining neonatal sepsis. Curr Opin Pediatr. (2016) 28:135-40. doi: 10.1097/MOP.0000000000000315
13. Fanaroff AA, Korones SB, Wright LL, Verter J, Poland RL, Bauer CR, et al. Incidence, presenting features, risk factors and significance of late onset septicemia in very low birth weight infants. The National Institute of Child Health and Human Development Neonatal Research Network. Pediatr Infect Dis J. (1998) 17:593-8
14. Shane AL, Sánchez PJ, Stoll BJ. Neonatal sepsis. Lancet (2017) 390:1770-80. doi: 10.1016/S0140-6736(17)31002-4
15. Gilfillan M, Bhandari V. Biomarkers for the diagnosis of neonatal sepsis and necrotizing enterocolitis: Clinical practice guidelines. Early HumDev. (2017) 105:25-33. doi: 10.1016/j.earlhumdev.2016.12.002
16. Juskewitch JE, Abraham RS, League SC, Jenkins SM, Smith CY, Enders FT, et al. Monocyte HLA-DR expression and neutrophil CD64 expression as biomarkers of infection in critically ill neonates and infants. Pediatr Res. (2015) 78:683-90. doi: 10.1038/pr.2015.164
17. Topcuoglu S, Arslanbuga C, Gursoy T, Aktas A, Karatekin G, Uluhan R, et al. Role of presepsin in the diagnosis of late-onset neonatal sepsis in preterm infants. J Matern Neonatal Med. (2015) 29:1-6. doi: 10.3109/14767058.2015.1064885
18. Dickinson P, Smith CL, Forster T, CraigonM, Ross AJ, KhondokerMR, et al. Whole blood gene expression profiling of neonates with confirmed bacterial sepsis. Genomics data (2015) 3:41-8. doi: 10.1016/j.gdata.2014.11.003
19. Wynn JL, Wong HR. Pathophysiology and treatment of septic shock in neonates. Clin Perinatol. (2010) 37:439-79. doi: 10.1016/j.clp.2010. 04.002
20. Zhao J, Kim KD, Yang X, Auh S, Fu Y-X, Tang H. Hyper innate responses in neonates lead to increased morbidity and mortality after infection. Proc Natl Acad Sci USA. (2008) 105:7528-33. doi: 10.1073/pnas.0800152105
21. Boomer JS, To K, Chang KC, Takasu O, Osborne DF, Walton AH, et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA (2011) 306:2594-605. doi: 10.1001/jama.2011.1829
22. Raymond SL, López MC, Baker HV, Larson SD, Efron PA, Sweeney TE, et al. Unique transcriptomic response to sepsis is observed among patients of different age groups. PLoS ONE (2017) 12:e0184159. doi: 10.1371/journal.pone.0184159
23. Tang BMP, McLean AS, Dawes IW, Huang SJ, Lin RCY. Gene-expression profiling of peripheral blood mononuclear cells in sepsis*. Crit Care Med. (2009) 37:882-8. doi: 10.1097/CCM.0b013e31819b52fd
24. Wynn JL, Cvijanovich NZ, Allen GL, Thomas NJ, Freishtat RJ, Anas N, et al. The influence of developmental age on the early transcriptomic response of children with septic shock. Mol Med. (2011) 17:1146-56. doi: 10.2119/molmed.2011.00169
25. Boomer JS, Green JM, Hotchkiss RS. The changing immune systemin sepsis: is individualized immuno-modulatory therapy the answer? Virulence (2014) 5:45-56. doi: 10.4161/viru.26516
26. Maslove DM, Wong HR. Gene expression profiling in sepsis: timing, tissue, and translational considerations. Trends Mol Med. (2014) 20:204-13. doi: 10.1016/j.molmed.2014.01.006
27. Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis. (2013) 13:260-8. doi: 10.1016/S1473-3099(13)70001-X
28. Tang BM, Huang SJ, McLean AS. Genome-wide transcription profiling of human sepsis: a systematic review. Crit Care (2010) 14:R237. doi: 10.1186/cc9392
29. Wynn JL, Guthrie SO, Wong HR, Lahni P, Ungaro R, Lopez MC, et al. Postnatal age is a critical determinant of the neonatal host response to sepsis. Mol Med. (2015) 21:496-504. doi: 10.2119/molmed.2015.00064
30. Ulas T, Pirr S, Fehlhaber B, Bickes MS, Loof TG, Vogl T, et al. S100-alarmininduced innate immune programming protects newborn infants fromsepsis. Nat Immunol. (2017) 18:622-32. doi: 10.1038/ni.3745
31. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol. (2006) 81:1-5. doi: 10.1189/jlb.0306164
32. Kollmann TR, Levy O, Montgomery RR, Goriely S. Innate immune function by Toll-like receptors: distinct responses in newborns and the elderly. Immunity (2012) 37:771-83. doi: 10.1016/j.immuni.2012.10.014
33. van Well GTJ, Daalderop LA, Wolfs T, Kramer BW. Human perinatal immunity in physiological conditions and during infection.Mol Cell Pediatr. (2017) 4:4. doi: 10.1186/s40348-017-0070-1
34. Dowling DJ, Levy O. Ontogeny of early life immunity. Trends Immunol. (2014) 35:299-310. doi: 10.1016/j.it.2014.04.007
35. Zilow EP, HauckW, Linderkamp O, Zilow G. Alternative pathway activation of the complement system in preterm infants with early onset infection. Pediatr Res. (1997) 41:334-9. doi: 10.1203/00006450-199703000-00005
36. Bektas S, Goetze B, Speer CP. Decreased adherence, chemotaxis and phagocytic activities of neutrophils from preterm neonates. Acta Paediatr Scand. (1990) 79:1031-8
37. Levy O. Innate immunity of the newborn: basic mechanisms and clinical correlates. Nat Rev Immunol. (2007) 7:379-90. doi: 10.1038/nri2075
38. Förster-Waldl E, Sadeghi K, Tamandl D, Gerhold B, Hallwirth U, Rohrmeister K, et al. Monocyte toll-like receptor 4 expression and LPSinduced cytokine production increase during gestational aging. Pediatr Res. (2005) 58:121-4. doi: 10.1203/01.PDR.0000163397.53466.0F
39. Schüller SS, Sadeghi K, Wisgrill L, Dangl A, Diesner SC, Prusa AR, et al. Preterm neonates display altered plasmacytoid dendritic cell function and morphology. J Leukoc Biol. (2013) 93:781-8. doi: 10.1189/jlb.1011525
40. Burl S, Townend J, Njie-Jobe J, Cox M, Adetifa UJ, Touray E, et al. Age-dependent maturation of Toll-like receptor-mediated cytokine responses in Gambian infants. PLoS ONE (2011) 6:e18185. doi: 10.1371/journal.pone.0018185
41. Belderbos ME, Levy O, Meyaard L, Bont L. Plasma-mediated immune suppression: a neonatal perspective. Pediatr Allergy Immunol. (2013) 24:102-13. doi: 10.1111/pai.12023
42. Power Coombs MR, Belderbos ME, Gallington LC, Bont L, Levy O. Adenosine modulates Toll-like receptor function: basic mechanisms and translational opportunities. Expert Rev Anti Infect Ther. (2011) 9:261-9. doi: 10.1586/eri.10.158
43. Haskó G, Kuhel DG, Chen JF, Schwarzschild MA, Deitch EA, Mabley JG, et al. Adenosine inhibits IL-12 and TNF-[alpha] production via adenosine A2a receptor-dependent and independent mechanisms. FASEB J. (2000) 14:2065-74. doi: 10.1096/fj.99-0508com
44. Haskó G, Cronstein BN. Adenosine: an endogenous regulator of innate immunity. Trends Immunol. (2004) 25:33-9. doi: 10.1016/j.it.2003.11.003
45. Mitchell MD, Lucas A, Etches PC, Brunt JD, Turnbull AC. Plasma prostaglandin levels during early neonatal life following term and pre-term delivery. Prostaglandins (1978) 16:319-26
46. Kauppila A, Koivisto M, Pukka M, Tuimala R. Umbilical cord and neonatal cortisol levels. Effect of gestational and neonatal factors. Obstet Gynecol. (1978) 52:666-72
47. Giannoni E, Guignard L, Knaup Reymond M, Perreau M, Roth-Kleiner M, Calandra T, et al. Estradiol and progesterone strongly inhibit the innate immune response of mononuclear cells in newborns. Infect Immun. (2011) 79:2690-8. doi: 10.1128/IAI.00076-11
48. PettengillM, Robson S, TresenriterM, Millán JL, Usheva A, BinghamT, et al. Soluble ecto-5'-nucleotidase (5'-NT), alkaline phosphatase, and adenosine deaminase (ADA1) activities in neonatal blood favor elevated extracellular adenosine. J Biol Chem. (2013) 288:27315-26. doi: 10.1074/jbc.M113. 484212
49. Roger T, Schneider A, Weier M, Sweep FCGJ, Le Roy D, Bernhagen J, et al. High expression levels of macrophage migration inhibitory factor sustain the innate immune responses of neonates. Proc Natl Acad Sci USA. (2016) 113:E997-1005. doi: 10.1073/pnas.1514018113
50. Roger T, Schlapbach LJ, Schneider A, WeierM, Wellmann S, Marquis P, et al. Plasma Levels of macrophage migration inhibitory factor and d-dopachrome tautomerase show a highly specific profile in early life. Front Immunol. (2017) 8:26. doi: 10.3389/fimmu.2017.00026
51. Wynn JL, Wilson CS, Hawiger J, Scumpia PO, Marshall AF, Liu J-H, et al. Targeting IL-17A attenuates neonatal sepsis mortality induced by IL-18. Proc Natl Acad Sci USA. (2016) 113:E2627-35. doi: 10.1073/pnas.1515793113
52. Levy O, Jean-Jacques RM, Cywes C, Sisson RB, Zarember KA, Godowski PJ, et al. Critical role of the complement system in group B streptococcusinduced tumor necrosis factor alpha release. Infect Immun. (2003) 71:6344-53. doi: 10.1128/iai.71.11.6344-6353.2003
53. Ehrnström B, Beckwith KS, Yurchenko M, Moen SH, Kojen JF, Lentini G, et al. Toll-Like receptor 8 is a major sensor of group bstreptococcusbut notescherichia coliin human primary monocytes and macrophages. Front Immunol. (2017) 8:1243. doi: 10.3389/fimmu.2017.01243
54. Ugolini M, Gerhard J, Burkert S, Jensen KJ, Georg P, Ebner F, et al. Recognition of microbial viability via TLR8 drives TFH cell differentiation and vaccine responses. Nat Immunol. (2018) 19:386-96. doi: 10.1038/s41590-018-0068-4
55. Moretti J, Blander JM. Detection of a vita-PAMP STINGs cells into reticulophagy. Autophagy (2018). doi: 10.1080/15548627.2018.1441471. [Epub ahead of print]
56. Blander JM, Sander LE. Beyond pattern recognition: five immune checkpoints for scaling the microbial threat. Nat Rev Immunol. (2012) 12:215-25. doi: 10.1038/nri3167
57. Sharma AA, Jen R, Kan B, Sharma A, Marchant E, Tang A, et al. Impaired NLRP3 inflammasome activity during fetal development regulates IL-1b production in human monocytes. Eur J Immunol. (2015) 45:238-49. doi: 10.1002/eji.201444707
58. Austermann J, Friesenhagen J, Fassl SK, Petersen B, Ortkras T, Burgmann J, et al. Alarmins MRP8 and MRP14 induce stress tolerance in phagocytes under sterile inflammatory conditions. Cell Rep. (2014) 9:2112-23. doi: 10.1016/j.celrep.2014.11.020
59. Romero R, Chaiworapongsa T, Alpay Savasan Z, Xu Y, Hussein Y, Dong Z, et al. Damage-associated molecular patterns (DAMPs) in preterm labor with intact membranes and preterm PROM: a study of the alarmin HMGB1. J Matern Neonatal Med. (2011) 24:1444-55. doi: 10.3109/14767058.2011.591460
60. Strunk T, Doherty D, Jacques MBiostat A, Simmer K, Richmond P, Kohan R, et al. Histologic chorioamnionitis is associated with reduced risk of late-onset sepsis in preterm infants. Pediatrics (2012) 129:e134-41. doi: 10.1542/peds.2010-3493
61. Scheible KM, Emo J, Yang H, Holden-Wiltse J, Straw A, Huyck H, et al. Developmentally determined reduction in CD31 during gestation is associated with CD8+ T cell effector differentiation in preterm infants. Clin Immunol. (2015) 161:65-74. doi: 10.1016/j.clim.2015.07.003
62. Luciano AA, Arbona-Ramirez IM, Ruiz R, Llorens-Bonilla BJ, Martinez-Lopez DG, Funderburg N, et al. Alterations in regulatory t cell subpopulations seen in preterm infants. PLoS ONE (2014) 9:e95867. doi: 10.1371/journal.pone.0095867
63. Gervassi A, Lejarcegui N, Dross S, Jacobson A, Itaya G, Kidzeru E, et al. Myeloid derived suppressor cells are present at high frequency in neonates and suppress in vitro t cell responses. PLoS ONE (2014) 9:e107816. doi: 10.1371/journal.pone.0107816
64. Rieber N, Gille C, Köstlin N, Schäfer I, Spring B, Ost M, et al. Neutrophilic myeloid-derived suppressor cells in cord blood modulate innate and adaptive immune responses. Clin Exp Immunol. (2013) 174:45-52. doi: 10.1111/cei.12143
65. Dreschers S, Saupp P, Hornef M, Prehn A, Platen C, Morschhäuser J, et al. Reduced PICD in monocytes mounts altered neonate immune response to Candida albicans. PLoS ONE (2016) 11:e0166648. doi: 10.1371/journal.pone.0166648
66. Gille C, Leiber A, Spring B, Kempf VAJ, Loeffler J, Poets CF, et al. Diminished Phagocytosis-Induced Cell Death (PICD) in Neonatal Monocytes upon Infection with Escherichia coli. Pediatr Res. (2008) 63:33-8. doi: 10.1203/PDR.0b013e31815b8e9f
67. O'Driscoll DN, Greene CM, Molloy EJ. Immune function? A missing link in the gender disparity in preterm neonatal outcomes. Expert Rev Clin Immunol. (2017) 13:1061-71. doi: 10.1080/1744666X.2017.1386555
68. Sampath V, Mulrooney N, Patel AL, Cohen J, Zhang L, Garland J, et al. A potential role for the NOD1 Variant (rs6958571) in Gram-positive blood stream infection in ELBW infants. Neonatology (2017) 112:354-8. doi: 10.1159/000477433
69. Esposito S, Zampiero A, Pugni L, Tabano S, Pelucchi C, Ghirardi B, et al. Genetic polymorphisms and sepsis in premature neonates. PLoS ONE (2014) 9:e101248. doi: 10.1371/journal.pone.0101248
70. Amenyogbe N, Kollmann TR, Ben-Othman R. Early-life host-microbiome interphase: the key frontier for immune development. Front Pediatr. (2017) 5:111. doi: 10.3389/fped.2017.00111
71. Gerdes JS. Diagnosis and management of bacterial infections in the neonate. Pediatr Clin North Am. (2004) 51:939-59. doi: 10.1016/j.pcl.2004.03.009
72. Smith CL, Dickinson P, Forster T, Craigon M, Ross A, Khondoker MR, et al. Identification of a human neonatal immune-metabolic network associated with bacterial infection. Nat Commun. (2014) 5:4649. doi: 10.1038/ncomms5649
73. Fragiadakis GK, Baca QJ, Gherardini PF, Ganio EA, Gaudilliere DK, Tingle M, et al. Mapping the fetomaternal peripheral immune system at term pregnancy. J Immunol. (2016) 197:4482-92. doi: 10.4049/jimmunol. 1601195
74. AmenyogbeN, LevyO, Kollmann TR. Systems vaccinology: a promise for the young and the poor. Philos Trans R Soc Lond B Biol Sci. (2015) 370:20140340. doi: 10.1098/rstb.2014.0340
75. Pammi M, Suresh G. Enteral lactoferrin supplementation for prevention of sepsis and necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev. (2017) 6:CD007137. doi: 10.1002/14651858.CD007137.pub5
76. EMA. Report on the ExpertMeeting on Neonatal and Paediatric Sepsis, 8 June2010. (2010)
77. Pammi M, Haque KN. Pentoxifylline for treatment of sepsis and necrotizing enterocolitis in neonates. Cochrane Database Syst Rev. (2015) 3:CD004205. doi: 10.1002/14651858.CD004205.pub3
78. Ohlsson A, Lacy JB. Intravenous immunoglobulin for suspected or proven infection in neonates. Cochrane Database Syst Rev. (2015) 3:CD001239. doi: 10.1002/14651858.CD001239.pub5
79. Carr R, Modi N, Doré C. G-CSF and GM-CSF for treating or preventing neonatal infections. Cochrane database Syst Rev. (2003) CD003066. doi: 10.1002/14651858.CD003066
80. Pammi M, Brocklehurst P. Granulocyte transfusions for neonates with confirmed or suspected sepsis and neutropenia. Cochrane Database Syst Rev. (2011) CD003956. doi: 10.1002/14651858.CD003956.pub2
81. Ohlsson A, Lacy JB. Intravenous immunoglobulin for preventing infection in preterm and/or low birth weight infants. In: Ohlsson A, editor. Cochrane Database of Systematic Reviews (Chichester: JohnWiley & Sons, Ltd), (2013) CD000361. doi: 10.1002/14651858.CD000361.pub2
82. Shah PS, Kaufman DA. Antistaphylococcal immunoglobulins to prevent staphylococcal infection in very low birth weight infants. Cochrane Database Syst Rev. (2009) CD006449. doi: 10.1002/14651858.CD006449.pub2
83. Patel M, Kaufman DA. Anti-lipoteichoic acid monoclonal antibody (pagibaximab) studies for the prevention of staphylococcal bloodstream infections in preterm infants. Expert Opin Biol Ther. (2015) 15:595-600. doi: 10.1517/14712598.2015.1019857
84. Weisman LE, Thackray HM, Steinhorn RH, Walsh WF, Lassiter HA, Dhanireddy R, et al. A randomized study of a monoclonal antibody (pagibaximab) to prevent staphylococcal sepsis. Pediatrics (2011) 128:271-9. doi: 10.1542/peds.2010-3081
85. Carr R, Brocklehurst P, Doré CJ, Modi N. Granulocyte-macrophage colony stimulating factor administered as prophylaxis for reduction of sepsis in extremely preterm, small for gestational age neonates (the PROGRAMS trial): a single-blind, multicentre, randomised controlled trial. Lancet (2009) 373:226-33. doi: 10.1016/S0140-6736(09)60071-4
86. Quigley M, McGuire W. Formula versus donor breast milk for feeding preterm or low birth weight infants. Coch Database Syst Rev. (2014) CD002971. doi: 10.1002/14651858.CD002971.pub3
87. Dermyshi E, Wang Y, Yan C, Hong W, Qiu G, Gong X, et al. The 'Golden Age' of probiotics: a systematic review and meta-analysis of randomized and observational studies in preterm infants. Neonatology (2017) 112:9-23. doi: 10.1159/000454668
88. Rao SC, Athalye-Jape GK, Deshpande GC, Simmer KN, Patole SK. Probiotic supplementation and late-onset sepsis in preterm infants: a meta-analysis. Pediatrics (2016) 137:e20153684. doi: 10.1542/peds.2015-3684
89. Agrawal S, Rao S, Patole S. Probiotic supplementation for preventing invasive fungal infections in preterm neonates-a systematic review and meta-analysis. Mycoses (2015) 58:642-51. doi: 10.1111/myc.12368
90. Chang H-Y, Chen J-H, Chang J-H, Lin H-C, Lin C-Y, Peng C-C. Multiple strains probiotics appear to be the most effective probiotics in the prevention of necrotizing enterocolitis and mortality: an updated meta-analysis. PLoS ONE (2017) 12:e0171579. doi: 10.1371/journal.pone.0171579
91. Moe-Byrne T, Brown JV, McGuireW.Glutamine supplementation to prevent morbidity and mortality in preterm infants. Cochrane Database Syst Rev. (2016) 4:CD001457. doi: 10.1002/14651858.CD001457.pub6
92. Darlow BA, Austin NC. Selenium supplementation to prevent shortterm morbidity in preterm neonates. Cochrane Database Syst Rev. (2003) CD003312. doi: 10.1002/14651858.CD003312
93. Kaufman D, Fairchild KD. Clinical microbiology of bacterial and fungal sepsis in very-low-birth-weight infants. Clin Microbiol Rev. (2004) 17:638-80. doi: 10.1128/CMR.17.3.638-680.2004
94. van den Berg JP, Westerbeek EAM, van der Klis FRM, Berbers GAM, van Elburg RM. Transplacental transport of IgG antibodies to preterm infants: a review of the literature. Early Hum Dev. (2011) 87:67-72. doi: 10.1016/j.earlhumdev.2010.11.003
95. Shankar-Hari M, Spencer J, Sewell WA, Rowan KM, Singer M. Bench-tobedside review: Immunoglobulin therapy for sepsis-biological plausibility froma critical care perspective. Crit Care (2012) 16:206. doi: 10.1186/cc10597
96. Benjamin DK, Schelonka R, White R, Holley HP, Bifano E, Cummings J, et al. A blinded, randomized, multicenter study of an intravenous Staphylococcus aureus immune globulin. J Perinatol. (2006) 26:290-5. doi: 10.1038/sj.jp.7211496
97. Baker CJ, Melish ME, Hall RT, Casto DT, Vasan U, Givner LB. Intravenous immune globulin for the prevention of nosocomial infection in low-birth-weight neonates. N Engl J Med. (1992) 327:213-9. doi: 10.1056/NEJM199207233270401
98. INIS Collaborative Group, Brocklehurst P, Farrell B, King A, Juszczak E, Darlow B, Haque K, et al. Treatment of neonatal sepsis with intravenous immune globulin. N Engl J Med. (2011) 365:1201-11. doi: 10.1056/NEJMoa1100441
99. Sause WE, Buckley PT, Strohl WR, Lynch AS, Torres VJ. Antibody-based biologics and their promise to combat Staphylococcus aureus infections. Trends Pharmacol Sci. (2016) 37:231-41. doi: 10.1016/j.tips.2015.11.008
100. Tao K-M, Li X-Q, Yang L-Q, Yu W-F, Lu Z-J, Sun Y-M, et al. Glutamine supplementation for critically ill adults. Cochrane Database Syst Rev. (2014) CD010050. doi: 10.1002/14651858.CD010050.pub2
101. Tarnow-Mordi W, Isaacs D, Dutta S. Adjunctive immunologic interventions in neonatal sepsis. Clin Perinatol. (2010) 37:481-99. doi: 10.1016/j.clp.2009.12.002
102. Saugstad OD. Oxidative stress in the newborn-a 30-year perspective. Biol Neonate (2005) 88:228-36. doi: 10.1159/000087586
103. Belik J, González-Luis GE, Perez-Vizcaino F, Villamor E. Isoprostanes in fetal and neonatal health and disease. Free Radic Biol Med. (2010) 48:177-88. doi: 10.1016/j.freeradbiomed.2009.10.043
104. Aggarwal R, Gathwala G, Yadav S, Kumar P. Selenium supplementation for prevention of late-onset sepsis in very low birth weight preterm neonates. J Trop Pediatr. (2016) 62:185-93. doi: 10.1093/tropej/fmv096
105. D'Angelo G, Marseglia L, Reiter RJ, Buonocore G, Gitto E. Melatonin and neonatal sepsis: a promising antioxidant adjuvant agent. Am J Perinatol. (2017) 34:1382-8. doi: 10.1055/s-0037-1604244
106. El Frargy M, El-sharkawy HM, Attia GF. Use of melatonin as an adjuvant therapy in neonatal sepsis. J Neonatal Perinatal Med. (2015) 8:227-32. doi: 10.3233/NPM-15814072
107. Gitto E, Karbownik M, Reiter RJ, Tan DX, Cuzzocrea S, Chiurazzi P, et al. Effects of melatonin treatment in septic newborns. Pediatr Res. (2001) 50:756-60. doi: 10.1203/00006450-200112000-00021
108. El-Gendy FM, El-Hawy MA, Hassan MG. Beneficial effect of melatonin in the treatment of neonatal sepsis. J Matern Fetal Neonatal Med. (2017) 31:2299-303. doi: 10.1080/14767058.2017.1342794
109. Uberos J, Miras-Baldo M, Jerez-Calero A, Narbona-López E. Effectiveness of vitamin a in the prevention of complications of prematurity. Pediatr Neonatol. (2014) 55:358-62. doi: 10.1016/j.pedneo.2013.12.002
110. Haider BA, Sharma R, Bhutta ZA. Neonatal vitamin A supplementation for the prevention of mortality and morbidity in term neonates in low and middle income countries. Cochrane Database Syst Rev. (2017) 2:CD006980. doi: 10.1002/14651858.CD006980.pub3
111. Effect of Vitamin A in the Treatment of Neonatal Sepsis and Necrotizing Enterocolitis-Full Text View-ClinicalTrials.gov. Available online at: https:// clinicaltrials.gov/ct2/show/NCT00707785 [Accessed April 4, 2017]
112. Mathias B, Szpila BE, Moore FA, Efron PA, Moldawer LL. A review of GM-CSF Therapy in Sepsis. Medicine (Baltimore) (2015) 94:e2044. doi: 10.1097/MD.0000000000002044
113. Gille C, Steffen F, Lauber K, Keppeler H, Leiber A, Spring B, et al. Clearance of apoptotic neutrophils is diminished in cord blood monocytes and does not lead to reduced il-8 production. Pediatr Res. (2009) 66:507-12. doi: 10.1203/PDR.0b013e3181b9b470
114. Melvan JN, Bagby GJ, Welsh DA, Nelson S, Zhang P. Neonatal sepsis and neutrophil insufficiencies. Int Rev Immunol. (2010) 29:315-48. doi: 10.3109/08830181003792803
115. Christensen RD, Rothstein G. Exhaustion of mature marrow neutrophils in neonates with sepsis. J Pediatr. (1980) 96:316-8
116. Molloy EJ, O'Neill AJ, Grantham JJ, Sheridan-Pereira M, Fitzpatrick JM, Webb DW, et al. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor have differential effects on neonatal and adult neutrophil survival and function. Pediatr Res. (2005) 57:806-12. doi: 10.1203/01.PDR.0000156500. 13600.B5
117. Castagnola E, Dufour C. Role of G-CSF GM-CSF in the management of infections in preterm newborns: an update. Early Hum Dev. (2014) 90:S15-17 doi: 10.1016/S0378-3782(14)50005-9
118. Pugni L, Ronchi A, Bizzarri B, Consonni D, Pietrasanta C, Ghirardi B, et al. Exchange transfusion in the treatment of neonatal septic shock: a ten-year experience in a neonatal intensive care unit. Int J Mol Sci. (2016) 17:695. doi: 10.3390/ijms17050695
119. Aradhya AS, SundaramV, Kumar P, Ganapathy SM, Jain A, Rawat A. Double volume exchange transfusion in severe neonatal sepsis. Indian J Pediatr. (2016) 83:107-13. doi: 10.1007/s12098-015-1841-0
120. Jackson JC. Adverse events associated with exchange transfusion in healthy and ill newborns. Pediatrics (1997) 99:E7
121. Sarangi PP, Lee H, Kim M. Activated protein C action in inflammation. Br J Haematol. (2010) 148:817-33. doi: 10.1111/j.1365-2141.2009.08020.x
122. Thachil J, Toh CH, LeviM, Watson HG. The withdrawal of Activated Protein C from the use in patients with severe sepsis and DIC [Amendment to the BCSH guideline on disseminated intravascular coagulation]. Br J Haematol. (2012) 157:493-4. doi: 10.1111/j.1365-2141.2011.09019.x
123. Nadel S, Goldstein B, Williams MD, Dalton H, Peters M, Macias WL, et al. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet (2007) 369:836-43. doi: 10.1016/S0140-6736(07)60411-5
124. Kylat RI, Ohlsson A. Recombinant human activated protein C for severe sepsis in neonates. In: Kylat RI editor. Cochrane Database of Systematic Reviews (Chichester: JohnWiley & Sons, Ltd), (2012) CD005385. doi: 10.1002/14651858.CD005385.pub3
125. Caccavo D, Pellegrino NM, Altamura M, Rigon A, Amati L, Amoroso A, et al. Antimicrobial and immunoregulatory functions of lactoferrin and its potential therapeutic application. J Endotoxin Res. (2002) 8:403-17. doi: 10.1179/096805102125001000
126. Elass E, Masson M, Mazurier J, Legrand D. Lactoferrin inhibits the lipopolysaccharide-induced expression and proteoglycan-binding ability of interleukin-8 in human endothelial cells. Infect Immun. (2002) 70:1860-6. doi: 10.1128/iai.70.4.1860-1866.2002
127. Schüller SS, Wisgrill L, Herndl E, Spittler A, Förster-Waldl E, Sadeghi K, et al. Pentoxifylline modulates LPS-induced hyperinflammation in monocytes of preterm infants in vitro. Pediatr Res. (2017) 82:215-25. doi: 10.1038/pr.2017.41
128. Speer EM, DowlingDJ, Ozog LS, Xu J, Yang J, Kennady G, et al. Pentoxifylline inhibits TLR-and inflammasome-mediated in vitro inflammatory cytokine production in human blood with greater efficacy and potency in newborns. Pediatr Res. (2017) 81:806-16. doi: 10.1038/pr.2017.6
129. Anaya JM, Espinoza LR. Phosphodiesterase inhibitor pentoxifylline: an antiinflammatory/immunomodulatory drug potentially useful in some rheumatic diseases. J Rheumatol. (1995) 22:595-9
130. Sherman MP. New concepts of microbial translocation in the neonatal intestine: mechanisms and prevention. Clin Perinatol. (2010) 37:565-79. doi: 10.1016/j.clp.2010.05.006
131. Wisgrill L, Wessely I, Spittler A, Förster-Waldl E, Berger A, Sadeghi K. Human lactoferrin attenuates the proinflammatory response of neonatal monocyte-derived macrophages. Clin Exp Immunol. (2018) 192:315-24. doi: 10.1111/cei.13108
132. Kallapur SG, Nitsos I, Moss TJM, Polglase GR, Pillow JJ, Cheah F-C, et al. IL-1 mediates pulmonary and systemic inflammatory responses to chorioamnionitis induced by lipopolysaccharide. Am J Respir Crit CareMed. (2009) 179:955-61. doi: 10.1164/rccm.200811-1728OC
133. Nold MF, Mangan NE, Rudloff I, Cho SX, Shariatian N, Samarasinghe TD, et al. Interleukin-1 receptor antagonist prevents murine bronchopulmonary dysplasia induced by perinatal inflammation and hyperoxia. Proc Natl Acad Sci USA. (2013) 110:14384-9. doi: 10.1073/pnas.1306859110
134. Rudloff I, Cho SX, Bui CB, McLean C, Veldman A, Berger PJ, et al. Refining anti-inflammatory therapy strategies for bronchopulmonary dysplasia. J Cell Mol Med. (2017) 21:1128-38. doi: 10.1111/jcmm.13044
135. Liao J, Kapadia VS, Brown LS, Cheong N, Longoria C, Mija D, et al. The NLRP3 inflammasome is critically involved in the development of bronchopulmonary dysplasia. Nat Commun. (2015) 6:8977. doi: 10.1038/ncomms9977
136. Singh PK, Parsek MR, Greenberg EP, Welsh MJ. A component of innate immunity prevents bacterial biofilm development. Nature (2002) 417:552-5. doi: 10.1038/417552a
137. Elass-Rochard E, Legrand D, Salmon V, Roseanu A, Trif M, Tobias PS, et al. Lactoferrin inhibits the endotoxin interaction with CD14 by competition with the lipopolysaccharide-binding protein. Infect Immun (1998) 66:486-91
138. Kawasaki Y, Tazume S, Shimizu K, Matsuzawa H, Dosako S, Isoda H, et al. Inhibitory effects of bovine lactoferrin on the adherence of enterotoxigenic Escherichia coli to host cells. Biosci Biotechnol Biochem. (2000) 64:348-54
139. Ochoa TJ, Noguera-Obenza M, Ebel F, Guzman CA, Gomez HF, Cleary TG. Lactoferrin impairs type III secretory system function in enteropathogenic Escherichia coli. Infect Immun. (2003) 71:5149-55
140. Ballard O, Morrow AL. Human milk composition: nutrients and bioactive factors. Pediatr Clin North Am. (2013) 60:49-74. doi: 10.1016/j.pcl.2012.10.002
141. Schanler RJ, Shulman RJ, Lau C. Feeding strategies for premature infants: beneficial outcomes of feeding fortified human milk versus preterm formula. Pediatrics (1999) 103:1150-7
142. de Silva A, Jones PW, Spencer SA. Does human milk reduce infection rates in preterm infants? A systematic review. Arch Dis Child (2004) 89:F509-13. doi: 10.1136/adc.2003.045682
143. Cacho NT, Lawrence RM. Innate immunity and breast milk. Front Immunol. (2017) 8:584. doi: 10.3389/fimmu.2017.00584
144. Underwood MA. Human milk for the premature infant. Pediatr Clin North Am. (2013) 60:189-207. doi: 10.1016/j.pcl.2012.09.008
145. Cacho NT, Parker LA, Neu J. Necrotizing enterocolitis and human milk feeding: a systematic review. Clin Perinatol. (2017) 44:49-67. doi: 10.1016/j.clp.2016.11.009
146. Meier P, Patel A, Esquerra-Zwiers A. Donor human milk update: evidence, mechanisms, and priorities for research and practice. J Pediatr. (2017) 180:15-21. doi: 10.1016/j.jpeds.2016.09.027
147. Kreissl A, Zwiauer V, Repa A, Binder C, Thanhaeuser M, Jilma B, et al. Human milk analyser shows that the lactation period affects protein levels in preterm breastmilk. Acta Paediatr. (2016) 105:635-40. doi: 10.1111/apa.13348
148. Gormaz M, Torres-Cuevas I, Cernada M, Kuligowski J, Cubells E, Escobar J, et al. Role of human milk in oxidative stress associated with prematurity. J Pediatr Biochem. (2013) 3:169-77. doi: 10.3233/JPB-130090
149. Peila C, Moro GE, Bertino E, Cavallarin L, Giribaldi M, Giuliani F, et al. The effect of holder pasteurization on nutrients and biologicallyactive components in donor human milk: a review. Nutrients (2016) 8:477. doi: 10.3390/nu8080477
150. Daniels B, Schmidt S, King T, Israel-Ballard K, Amundson Mansen K, Coutsoudis A. The effect of simulated flash-heat pasteurization on immune components of human milk. Nutrients (2017) 9:178. doi: 10.3390/nu9020178
151. Villamor-Martínez E, Pierro M, Cavallaro G, Mosca F, Kramer BW, Villamor E. Donor human milk protects against bronchopulmonary dysplasia: a systematic review and meta-analysis. Nutrients (2018) 10:238. doi: 10.3390/nu10020238
152. Gibson GR, Hutkins R, Sanders ME, Prescott SL, Reimer RA, Salminen SJ, et al. Expert consensus document: the international scientific association for probiotics and prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol. (2017) 14:491-502. doi: 10.1038/nrgastro.2017.75
153. Jakaitis BM, Denning PW. Human breast milk and the gastrointestinal innate immune system. Clin Perinatol. (2014) 41:423-35. doi: 10.1016/j.clp.2014.02.011
154. Nair V, Soraisham AS. Probiotics and prebiotics: role in prevention of nosocomial sepsis in preterm infants. Int J Pediatr. (2013) 2013:874726. doi: 10.1155/2013/874726
155. Sanders ME, Guarner F, Guerrant R, Holt PR, Quigley EM, Sartor RB, et al. An update on the use and investigation of probiotics in health and disease. Gut (2013) 62:787-96. doi: 10.1136/gutjnl-2012-302504
156. Madan JC, Salari RC, Saxena D, Davidson L, O'Toole GA, Moore JH, Sogin ML, et al. Gut microbial colonisation in premature neonates predicts neonatal sepsis. Arch Dis Child Fetal Neonatal Ed. (2012) 97:F456-62. doi: 10.1136/fetalneonatal-2011-301373
157. AlFaleh K, Anabrees J. Probiotics for prevention of necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev. (2014) CD005496. doi: 10.1002/14651858.CD005496.pub4
158. Deshpande G, Jape G, Rao S, Patole S. Benefits of probiotics in preterm neonates in low-income and medium-income countries: a systematic review of randomised controlled trials. BMJ Open (2017) 7:e017638. doi: 10.1136/bmjopen-2017-017638
159. Dani C, Coviello C C, Corsini I I, Arena F, Antonelli A, Rossolini GM. Lactobacillus sepsis and probiotic therapy in newborns: two new cases and literature review. AJP Rep. (2016) 6:e25-9. doi: 10.1055/s-0035-1566312
160. Panigrahi P, Parida S, Nanda NC, Satpathy R, Pradhan L, Chandel DS, et al. A randomized synbiotic trial to prevent sepsis among infants in rural India. Nature (2017) 548:407-12. doi: 10.1038/nature23480
161. Embleton ND, Zalewski S, Berrington JE. Probiotics for prevention of necrotizing enterocolitis and sepsis in preterm infants. Curr Opin Infect Dis. (2016) 29:256-61. doi: 10.1097/QCO.0000000000000269
162. Kruzel ML, Zimecki M, Actor JK. Lactoferrin in a context of inflammation-induced pathology. Front Immunol. (2017) 8:1438. doi: 10.3389/fimmu.2017.01438
163. Elass-Rochard E, Roseanu A, Legrand D, Trif M, Salmon V, Motas C, et al. Lactoferrin-lipopolysaccharide interaction: involvement of the 28-34 loop region of human lactoferrin in the high-affinity binding to Escherichia coli 055B5 lipopolysaccharide. Biochem J. (1995) 312 ( Pt 3):839-45
164. Curran CS, Demick KP, Mansfield JM. Lactoferrin activates macrophages via TLR4-dependent and-independent signaling pathways. Cell Immunol. (2006) 242:23-30. doi: 10.1016/j.cellimm.2006.08.006
165. Zimecki M, Wlaszczyk A, Zagulski T, Kübler A. Lactoferrin lowers serum interleukin 6 and tumor necrosis factor alpha levels in mice subjected to surgery. Arch Immunol Ther Exp. (Warsz) (1998) 46:97-104
166. Zimecki M, Wlaszczyk A, Wojciechowski R, Dawiskiba J, Kruzel M. Lactoferrin regulates the immune responses in post-surgical patients. Arch Immunol Ther Exp. (Warsz) (2001) 49:325-33
167. Kruzel ML, Actor JK, Boldogh I, Zimecki M. Lactoferrin in health and disease. Postepy Hig Med Dosw (Online) (2007) 61:261-7
168. Pierce A, Colavizza D, Benaissa M, Maes P, Tartar A, Montreuil J, et al. Molecular cloning and sequence analysis of bovine lactotransferrin. Eur J Biochem. (1991) 196:177-84
169. Manzoni P, Rinaldi M, Cattani S, Pugni L, Romeo MG, Messner H, et al. Bovine lactoferrin supplementation for prevention of lateonset sepsis in very low-birth-weight neonatesa randomized trial JAMA (2009) 302:1421. doi: 10.1001/jama.2009.1403
170. ShermanMP, Adamkin DH, Niklas V, Radmacher P, Sherman J, Wertheimer F, et al. Randomized controlled trial of talactoferrin oral solution in preterm infants. J Pediatr. (2016) 175:68-73.e3. doi: 10.1016/j.jpeds.2016.04.084
171. Strunk T, Hibbert J, Doherty D, Granland C, Trend S, Simmer K, et al. Probiotics and antimicrobial protein and peptide levels in preterm infants. Acta Paediatr. (2017) 106:1747-53. doi: 10.1111/apa.13826
172. Gammoh NZ, Rink L. Zinc in Infection and Inflammation. Nutrients (2017) 9:624. doi: 10.3390/nu9060624
173. Prasad AS. Zinc: mechanisms of host defense. J Nutr. (2007) 137:1345-9. doi: 10.1093/jn/137.5.1345
174. Bhatnagar S, Wadhwa N, Aneja S, Lodha R, Kabra SK, Natchu UCM, et al. Zinc as adjunct treatment in infants aged between 7 and 120 days with probable serious bacterial infection: a randomised, double-blind, placebo-controlled trial. Lancet (2012) 379:2072-8. doi: 10.1016/S0140-6736(12)60477-2
175. Terrin G, Berni Canani R, Passariello A, Messina F, Conti MG, Caoci S, Smaldore A, et al. Zinc supplementation reduces morbidity and mortality in very-low-birth-weight preterm neonates: a hospital-based randomized, placebo-controlled trial in an industrialized country. Am J Clin Nutr. (2013) 98:1468-74. doi: 10.3945/ajcn.112.054478
176. Mehta K, Bhatta NK, Majhi S, Shrivastava MK, Singh RR. Oral zinc supplementation for reducing mortality in probable neonatal sepsis: a double blind randomized placebo controlled trial. Indian Pediatr. (2013) 50:390-3. doi: 10.1007/s13312-013-0120-2
177. Banupriya N, Bhat BV, Benet BD, Catherine C, Sridhar MG, Parija SC. Short term oral zinc supplementation among babies with neonatal sepsis for reducing mortality and improving outcome-a doubleblind randomized controlled trial. Indian J Pediatr. (2018) 85:5-9. doi: 10.1007/s12098-017-2444-8
178. Tang Z, Wei Z, Wen F, Wu Y. Efficacy of zinc supplementation for neonatal sepsis: a systematic review and meta-analysis. J Matern Fetal Neonatal Med. (2017). doi: 10.1080/14767058.2017.1402001. [Epub ahead of print]
179. Staub E, Evers K, Askie LM. Enteral zinc supplementation for prevention of morbidity and mortality in preterm neonates (Protocol). Coch Database Syst Rev. (2017) CD012797. doi: 10.1002/14651858.CD012797
180. Speer EM, Dowling DJ, Xu J, Ozog LS, Mathew JA, Chander A, et al. Pentoxifylline, dexamethasone and azithromycin demonstrate distinct agedependent and synergistic inhibition of TLR-and inflammasome-mediated cytokine production in human newborn and adult blood in vitro. PLoS ONE (2018) 13:e0196352. doi: 10.1371/journal.pone.0196352
181. Shabaan AE, Nasef N, Shouman B, Nour I, Mesbah A, Abdel-Hady H. Pentoxifylline therapy for late-onset sepsis in preterm infants: a randomized controlled trial. Pediatr Infect Dis J. (2015) 34:e143-8. doi: 10.1097/INF.0000000000000698
182. Jones CE, Calvert A, Le Doare K. Vaccination in pregnancy-recent developments. Pediatr Infect Dis J. (2018) 37:191-3. doi: 10.1097/INF.0000000000001822
183. Heath PT, Culley FJ, Jones CE, Kampmann B, Le Doare K, Nunes MC, et al. Group B streptococcus and respiratory syncytial virus immunisation during pregnancy: a landscape analysis. Lancet Infect Dis. (2017) 17:e223-4. doi: 10.1016/S1473-3099(17)30232-3
184. Krause PR, Bialek SR, Boppana SB, Griffiths PD, Laughlin CA, Ljungman P, et al. Priorities for CMV vaccine development. Vaccine (2013) 32:4-10. doi: 10.1016/j.vaccine.2013.09.042
185. Munoz FM, Piedra PA, Glezen WP. Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women. Vaccine (2003) 21:3465-7. doi: 10.1016/s0264-410x(03)00352-9
186. van den Berg JP, Westerbeek EAM, Smits GP, van der Klis FRM, Berbers GAM, van Elburg RM. Lower transplacental antibody transport for measles, mumps, rubella and varicella zoster in very preterm infants. PLoS ONE (2014) 9:e94714. doi: 10.1371/journal.pone.0094714
187. Marchant A, Sadarangani M, Garand M, Dauby N, Verhasselt V, Pereira L, et al. Maternal immunisation: collaborating with mother nature. Lancet Infect Dis. (2017) 17:e197-208. doi: 10.1016/S1473-3099(17)30229-3
188. Martin L, van Meegern A, Doemming S, Schuerholz T. Antimicrobial peptides in human sepsis. Front Immunol. (2015) 6:404. doi: 10.3389/fimmu.2015.00404
189. Huttner KM, Bevins CL. Antimicrobial peptides as mediators of epithelial host defense. Pediatr Res. (1999) 45:785-94. doi: 10.1203/00006450-199906000-00001
190. Battersby AJ, Khara J, Wright VJ, Levy O, Kampmann B. Antimicrobial proteins and peptides in early life: ontogeny and translational opportunities. Front Immunol. (2016) 7:309. doi: 10.3389/fimmu.2016.00309
191. Kai-Larsen Y, Gudmundsson GH, Agerberth B. A review of the innate immune defence of the human foetus and newborn, with the emphasis on antimicrobial peptides. Acta Paediatr. (2014) 103:1000-8. doi: 10.1111/apa.12700
192. Pammi M, Abrams SA. Oral lactoferrin for the prevention of sepsis and necrotizing enterocolitis in preterm infants. In: Pammi M editor. Cochrane Database of Systematic Reviews (Chichester: John Wiley & Sons, Ltd) (2015) CD007137. doi: 10.1002/14651858.CD007137.pub4
193. Levin M, Quint PA, Goldstein B, Barton P, Bradley JS, Shemie SD, et al. Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 Meningococcal Sepsis Study Group. Lancet (2000) 356:961-7. doi: 10.1016/s0140-6736(00)02712-4
194. Giroir BP, Scannon PJ, Levin M. Bactericidal/permeability-increasing protein-lessons learned from the phase III, randomized, clinical trial of rBPI21 for adjunctive treatment of children with severe meningococcemia. Crit Care Med. (2001) 29:S130-5. doi: 10.1097/00003246-200107001-00039
195. Silva ON, de la Fuente-Núñez C, Haney EF, Fensterseifer ICM, Ribeiro SM, Porto WF, et al. An anti-infective synthetic peptide with dual antimicrobial and immunomodulatory activities. Sci Rep. (2016) 6:35465. doi: 10.1038/srep35465
196. Mansour SC, de la Fuente-Núñez C, Hancock REW. Peptide IDR-1018: modulating the immune system and targeting bacterial biofilms to treat antibiotic-resistant bacterial infections. J Pept Sci. (2015) 21:323-9. doi: 10.1002/psc.2708
197. Wynn JL, Scumpia PO, Winfield RD, Delano MJ, Kelly-Scumpia K, Barker T, et al. Defective innate immunity predisposes murine neonates to poor sepsis outcome but is reversed by TLR agonists. Blood (2008) 112:1750-8. doi: 10.1182/blood-2008-01-130500
198. Sharma AA, Jen R, Brant R, Ladd M, Huang Q, Skoll A, et al. Hierarchical maturation of innate immune defences in very preterm neonates. Neonatology (2014) 106:1-9. doi: 10.1159/000358550
199. Schüller S, Wisgrill L, Sadeghi K, Gindl E, Helmer H, Husslein P, et al. The TLR-specific Adjuvants R-848 and CpG-B endorse the immunological reaction of neonatal antigen presenting cells. Pediatr Res. (2016) 80:311-8. doi: 10.1038/pr.2016.71
200. Savva A, Roger T. Targeting toll-like receptors: promising therapeutic strategies for the management of sepsis-associated pathology and infectious diseases. Front Immunol. (2013) 4:387. doi: 10.3389/fimmu.2013.00387
201. Rincon JC, Cuenca AL, Raymond SL, Mathias B, Nacionales DC, Ungaro R, et al. Adjuvant pretreatment with alum protects neonatal mice in sepsis through myeloid cell activation. Clin Exp Immunol. (2017) 191:268-78. doi: 10.1111/cei.13072
202. Li H, WillinghamSB, Ting JP-Y, Re F. Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3. J Immunol. (2008) 181:17-21. doi: 10.4049/jimmunol.181.1.17
203. Aaby P, Roth A, Ravn H, Napirna BM, Rodrigues A, Lisse IM, et al. Randomized trial of BCG vaccination at birth to low-birth-weight children: beneficial nonspecific effects in the neonatal period? J Infect Dis. (2011) 204:245-52. doi: 10.1093/infdis/jir240
204. Levy O, Netea MG. Innate immune memory: implications for development of pediatric immunomodulatory agents and adjuvanted vaccines. Pediatr Res. (2014) 75:184-8. doi: 10.1038/pr.2013.214
205. Scheid A, Borriello F, Pietrasanta C, Christou H, Diray-Arce J, Pettengill MA, et al. Adjuvant effect of bacille calmette-guérin on hepatitis b vaccine immunogenicity in the preterm and term newborn. Front Immunol. (2018) 9:29. doi: 10.3389/fimmu.2018.00029
206. Chamberlain G, Fox J, Ashton B, Middleton J. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells (2007) 25:2739-49. doi: 10.1634/stemcells.2007-0197
207. Cóndor JM, Rodrigues CE, Sousa Moreira R de, Canale D, Volpini RA, Shimizu MHM, et al. Treatment with human wharton's jelly-derived mesenchymal stemcells attenuates sepsis-induced kidney injury, liver injury, and endothelial dysfunction. Stem Cells Transl Med. (2016) 5:1048-57. doi: 10.5966/sctm.2015-0138
208. Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringdén O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol. (2003) 57:11-20. doi: 10.1046/j.1365-3083.2003.01176.x
209. Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts AI, et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell (2008) 2:141-50. doi: 10.1016/j.stem.2007.11.014
210. English K, Ryan JM, Tobin L, Murphy MJ, Barry FP, Mahon BP. Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells. Clin Exp Immunol. (2009) 156:149-60. doi: 10.1111/j.1365-2249.2009.03874.x
211. Krasnodembskaya A, Samarani G, Song Y, Zhuo H, Su X, Lee J-W, et al. Human mesenchymal stem cells reduce mortality and bacteremia in gramnegative sepsis in mice in part by enhancing the phagocytic activity of blood monocytes. Am J Physiol Lung Cell Mol Physiol. (2012) 302:L1003-13. doi: 10.1152/ajplung.00180.2011
212. Sung DK, Chang YS, Sung SI, Yoo HS, Ahn SY, ParkWS. Antibacterial effect of mesenchymal stem cells against Escherichia coli is mediated by secretion of beta-defensin-2 via toll-like receptor 4 signalling. Cell Microbiol. (2016) 18:424-36. doi: 10.1111/cmi.12522
213. Lalu MM, Sullivan KJ, Mei SH, Moher D, Straus A, Fergusson DA, et al. Evaluating mesenchymal stem cell therapy for sepsis with preclinical metaanalyses prior to initiating a first-in-human trial. Elife (2016) 5:e17850. doi: 10.7554/eLife.17850
214. Johnson CL, Soeder Y, Dahlke MH. Concise review: mesenchymal stromal cell-based approaches for the treatment of acute respiratory distress and sepsis syndromes. Stem Cells Transl Med. (2017) 6:1141-51. doi: 10.1002/sctm.16-0415
215. Galstian GM, Parovichnikova EN, Makarova PM, Kuzmina LA, Troitskaya VV. Gemdzhian E, et al. The results of the russian clinical trial of mesenchymal stromal cells (MSCs) in severe neutropenic patients (pts) with septic shock (SS) (RUMCESS trial). Blood (2015) 126:2220
216. Cellular Immunotherapy for Septic Shock: A Phase I Trial-Full Text View-ClinicalTrials.gov. Available online at: https://clinicaltrials.gov/ct2/show/ NCT02421484 [Accessed April 17, 2017]
217. Chang YS, Ahn SY, Yoo HS, Sung SI, Choi SJ, Oh W Il, et al. Mesenchymal stem cells for bronchopulmonary dysplasia: phase 1 dose-escalation clinical trial. J Pediatr. (2014) 164:966-72.e6. doi: 10.1016/j.jpeds.2013.12.011
218. Mercer JS, Vohr BR, McGrath MM, Padbury JF, Wallach M, Oh W. Delayed cord clamping in very preterm infants reduces the incidence of intraventricular hemorrhage and late-onset sepsis: a randomized, controlled trial. Pediatrics (2006) 117:1235-42. doi: 10.1542/peds.2005-1706
219. Wisgrill L, Schüller S, Bammer M, Berger A, Pollak A, Radke TF, et al. Hematopoietic stem cells in neonates: any differences between very preterm and term neonates? PLoS ONE (2014) 9:e106717. doi: 10.1371/journal.pone.0106717
220. Fogarty M, Osborn DA, Askie L, Seidler AL, Hunter K, Lui K, et al. Delayed vs early umbilical cord clamping for preterm infants: a systematic review and meta-analysis. Am J Obstet Gynecol. (2018) 218:1-18. doi: 10.1016/j.ajog.2017.10.231
221. Coll RC, Robertson AAB, Chae JJ, Higgins SC, Muñoz-Planillo R, Inserra MC, et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med. (2015) 21:248-55. doi: 10.1038/nm.3806
222. Shao B-Z, Xu Z-Q, Han B-Z, Su D-F, Liu C. NLRP3 inflammasome and its inhibitors: a review. Front Pharmacol. (2015) 6:262. doi: 10.3389/fphar.2015.00262
223. Cohen TS, Boland ML, Boland BB, Takahashi V, Tovchigrechko A, Lee Y, et al. S. aureus evades macrophage killing through NLRP3-dependent effects on mitochondrial trafficking. Cell Rep. (2018) 22:2431-41. doi: 10.1016/j.celrep.2018.02.027
224. Gentile LF, Cuenca AL, Cuenca AG, Nacionales DC, Ungaro R, Efron PA, et al. Improved emergency myelopoiesis and survival in neonatal sepsis by caspase-1/11 ablation. Immunology (2015) 145:300-11. doi: 10.1111/imm.12450
225. Fenini G, Contassot E, French LE. Potential of IL-1, IL-18 and Inflammasome Inhibition for the Treatment of Inflammatory Skin Diseases. Front Pharmacol. (2017) 8:278. doi: 10.3389/fphar.2017.00278
226. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. (2017) 377:1119-31. doi: 10.1056/NEJMoa1707914
227. Orman KL, English BK. Effects of antibiotic class on the macrophage inflammatory response to Streptococcus pneumoniae. J Infect Dis. (2000) 182:1561-5. doi: 10.1086/315861
228. von SethM, Sjölin J, Larsson A, ErikssonM, Hillered L, LipcseyM. Effects of tigecycline and doxycycline on inflammation and hemodynamics in porcine endotoxemia. Shock (2015) 43:604-11. doi: 10.1097/SHK.0000000000 000351
229. Krakauer T, Buckley M. Doxycycline is anti-inflammatory and inhibits staphylococcal exotoxin-induced cytokines and chemokines. Antimicrob Agents Chemother (2003) 47:3630-3. doi: 10.1128/aac.47.11.3630-3633.2003
230. Bi W, Zhu L, Jing X, Zeng Z, Liang Y, Xu A, et al. Rifampicin improves neuronal apoptosis in LPS-stimulated co-cultured BV2 cells through inhibition of the TLR-4 pathway. Mol Med Rep. (2014) 10:1793-9. doi: 10.3892/mmr.2014.2480
231. Altenburg J, de Graaff CS, van der Werf TS, Boersma WG. Immunomodulatory effects of macrolide antibiotics-part 1: biological mechanisms. Respiration (2011) 81:67-74. doi: 10.1159/000320319
232. Nair V, Loganathan P, Soraisham AS. Azithromycin and other macrolides for prevention of bronchopulmonary dysplasia: a systematic review and meta-analysis. Neonatology (2014) 106:337-47. doi: 10.1159/000363493
233. Kallapur SG, Kramer BW, Jobe AH. Ureaplasma and BPD. Semin Perinatol. (2013) 37:94-101. doi: 10.1053/j.semperi.2013.01.005
234. Gualdoni GA, Lingscheid T, Schmetterer KG, Hennig A, Steinberger P, Zlabinger GJ. Azithromycin inhibits IL-1 secretion and non-canonical inflammasome activation. Sci Rep. (2015) 5:12016. doi: 10.1038/srep12016
235. Lendermon EA, Coon TA, Bednash JS, Weathington NM, McDyer JF, Mallampalli RK. Azithromycin decreases NALP3 mRNA stability in monocytes to limit inflammasome-dependent inflammation. Respir Res. (2017) 18:131. doi: 10.1186/s12931-017-0608-8
236. Upadhyay K, Hiregoudar B, Meals E, English BK, Talati AJ. Combination therapy with ampicillin and azithromycin improved outcomes in a mouse model of group B streptococcal sepsis. PLoS ONE (2017) 12:e0182023. doi: 10.1371/journal.pone.0182023
237. Afshar M, Foster CL, Layden JE, Burnham EL. Azithromycin use and outcomes in severe sepsis patients with and without pneumonia. J Crit Care (2016) 32:120-5. doi: 10.1016/j.jcrc.2015.12.010
238. Ruiz VE, Battaglia T, Kurtz ZD, Bijnens L, Ou A, Engstrand I, et al. A single early-in-life macrolide course has lasting effects on murine microbial network topology and immunity. Nat Commun. (2017) 8:518. doi: 10.1038/s41467-017-00531-6
239. Murchison L, De Coppi P, Eaton S. Post-natal erythromycin exposure and risk of infantile hypertrophic pyloric stenosis: a systematic review and meta-analysis. Pediatr Surg Int. (2016) 32:1147-52. doi: 10.1007/s00383-016-3971-5
240. Eberly MD, Eide MB, Thompson JL, Nylund CM. Azithromycin in Early Infancy and Pyloric Stenosis. Pediatrics (2015) 135:483-8. doi: 10.1542/peds.2014-2026